share_log

西藏药业(600211.SH):正在根据市场需求统计2024年新活素预计销量

Tibet Pharmaceutical (600211.SH): The estimated sales volume of neovactin in 2024 is being calculated based on market demand

Gelonghui Finance ·  Mar 11 03:41

Gelonghui March 11 丨 Tibet Pharmaceutical (600211.SH) disclosed an investor relations activity record table showing that judging from the previous sales situation, it is normal for sales to fluctuate monthly and quarterly. Judging from the sales situation throughout the year, the development trend of neovactin will be more accurate. The specific sales data for the previous two months is still being counted. The company is counting the estimated sales volume of neovactin in 2024 based on market demand.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment